- Federal agenciesMakes manufacture and distribution without registration a federal crime, reducing unregulated market availability.
- Potential benefitGives law enforcement clearer authority to seize products and prosecute traffickers of tianeptine.
- Potential benefitFacilitates removal of tianeptine-containing products marketed as supplements from retail channels.
STAND Against Emerging Opioids Act
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
This bill amends the Controlled Substances Act to add tianeptine — including analogues, salts, isomers, and salts of isomers — to Schedule III. The scheduling becomes effective 90 days after enactment.
Progressives worry about criminalization; conservatives emphasize enforcement
Relative to its intended legislative type, this bill is a straightforward, narrowly scoped substantive amendment to the Controlled Substances Act that is mechanistically precise and provides a clear effective date, but it contains limited contextual justification, no fiscal or resourcing discussion, minimal consideration of edge cases (notably undefined "analogues"), and no added reporting or review provisions.
This bill amends the Controlled Substances Act to add tianeptine — including analogues, salts, isomers, and salts of isomers — to Schedule III.
The scheduling becomes effective 90 days after enactment.
Content is narrow and administrative so chances are reasonable, but congressional calendaring, possible stakeholder opposition, and procedural hurdles reduce probability.
Relative to its intended legislative type, this bill is a straightforward, narrowly scoped substantive amendment to the Controlled Substances Act that is mechanistically precise and provides a clear effective date, but it contains limited contextual justification, no fiscal or resourcing discussion, minimal consideration of edge cases (notably undefined "analogues"), and no added reporting or review provisions.
Progressives worry about criminalization; conservatives emphasize enforcement
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenMay lead to prosecutions or penalties for small sellers or individual users of tianeptine products.
- ManufacturersImposes compliance costs on manufacturers, distributors, and retailers handling tianeptine-containing goods.
- Potential burdenCould push remaining demand into illicit markets, reducing product quality controls and surveillance.
Why the argument around this bill splits.
Progressives worry about criminalization; conservatives emphasize enforcement
Likely supportive of public-health measures that reduce opioid harm, but wary of criminalization and access barriers.
Would emphasize treatment, harm reduction, and protecting research and medical access when implementing scheduling.
Will view this as a pragmatic regulatory response to reports of misuse.
Wants implementation details, fiscal impacts, and guardrails to avoid unintended consequences.
May support action that strengthens law enforcement against opioids, but cautious about expanding federal regulation and costs.
Would push for narrow scope and enforcement focus.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and administrative so chances are reasonable, but congressional calendaring, possible stakeholder opposition, and procedural hurdles reduce probability.
- Whether regulatory agencies (DEA/FDA) have already initiated scheduling actions
- Potential opposition from researchers or manufacturers affected by Schedule III status
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Progressives worry about criminalization; conservatives emphasize enforcement
Content is narrow and administrative so chances are reasonable, but congressional calendaring, possible stakeholder opposition, and procedu…
Relative to its intended legislative type, this bill is a straightforward, narrowly scoped substantive amendment to the Controlled Substances Act that is mechanistically precise and provides a clear effective date, but…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.